Seeking Alpha

FocalPoint Anal...'s  Instablog

FocalPoint Analytics
Send Message
I own and operate an analytical services/ research company.
My book:
The Internet in Everyday Life (Chapter 19)
  • Swine Flu News Concentrator (December 11 - December 31) 53 comments
    Dec 11, 2009 3:25 PM | about stocks: APT, BAX, BCRX, BDX, CBM, CLX, CVM, DGX, ECL, HOLX, GSK, INO, MMM, NVAX, NVS, PURE, ROG, SVA, VICL
    Explanation:

    I will post Swine-Flu and related articles under this heading.  The top of the instablog will contain my current months key links  preceded with a one or two liner that explains the link.  A more complete summary of the link will be in the comments area.  At the bottom of the Instablog we have definition of terms, a summary of Swine Flu / vaccine investment plays, the 2009 H1N1 Flu Outbreak Map, Red Cross Tips For Dealing With The Flu, and Memory Alpha which contains links to previous news concentrators and authors articles on the subject.

    I will be backing this up frequently as well.
    Last backup:   December 25 10:16 Pacific

    _____________________

    Update History:
    Added Overview of H1N1 / Categories of Vaccine Investment Plays Added Memory Alpha
    Added Link to Google's Swine Flu Infection Map
    Added Red Cross Tips for Dealing With The Flu
    Added definition of EUA and PREP act
    Broke Swine Flu Concentrator into two parts for October
    Broke Swine Flu Concentrator into three parts for October
    Added Swine Flu Concentrator November Part 1
    Bolded References to Older Swine Flu Concentrators in Memory Alpha
    Expanded the list of stocks discussed in the tags
    Alphabetized stocks in the tags
    Updated the play by stock list
    Added a table that contains the web site addresses for the companies discussed
    Moved links over one month old to the new Memory Alpha Reference Library
    Added definitions of Clinical Trials and Protocol.
    Corrected Roche stock symbol in the web site table
    _____________________
    December Links:

    Swine Flu News Concentrator (December 4 - December 11)
    seekingalpha.com/instablog/283977-user-2...

    Swine Flu News Concentrator (November 28 - December 4 Part 5)
    seekingalpha.com/instablog/283977-user-2...

    ___________________
    Some Definitions:

    Swine Flu - Novel H1N1 flu, popularly known as swine flu, is a respiratory infection caused by an influenza virus first recognized in spring 2009. The new virus, which is officially called swine influenza A (H1N1), contains genetic material from human, swine and avian flu viruses. (By Mayo Clinic staff)

    Pandemic - The word "pandemic" comes from the Greek "pan-", "all" + "demos", "people or population" = "pandemos" = "all the people." A pandemic affects all (nearly all) of the people.

    A World Health Organization phase 6 pandemic indicates that influenza due to the novel H1N1 swine flu is occurring in multiple countries around the world and that human infection is widespread. The classification does not reflect the severity of individual infections.

    Cytokine Storm -
    When our body detects foreign micro-organisms indicating an infection, our body might respond by over-protecting the site of infection. The body may race so many antibodies to the infection site that they collect in what is known as a cytokine storm.

    A cytokine storm, or "Hypercytokinemia" is a potentially fatal immune reaction consisting of a positive feedback loop between cytokines and immune cells.
    www.wisegeek.com/what-is-the-cytokine-st...

    A positive feedback loop means that as something increases, that increase stimulates further growth.

    What makes younger people more susceptible to H1N1 is that their “vigorous immune systems pour out antibodies to attack the new virus. That can inflame lung cells until they leak fluid, which can overwhelm the lungs.

    This vulnerability in the young is reminiscent of the Spanish flu of 1918. That strain of flu also struck mostly healthy young adults.

    Pulmonary Embolism - Occurs when a blood clot forms in an arm or leg breaks free and enters the lungs where it is too large to pass through the small vessels of the lungs and forms a blockage. This stops blood from flowing into an area of the lung, and the part of the lung dies because it does not receive oxygen.
    medicalnewstoday.com/articles/153796.php

    What is an Emergency Use Authorization (EUA)?
    An EUA may be issued by the Food and Drug Administration (FDA) to allow either the use of an unapproved medical product or an unapproved use of an approved medical product during certain types of emergencies with specified agents.

    What is the PREP Act?
    The PREP Act authorizes the Secretary of the Department of Health and Human Services (“Secretary”) to issue a declaration (“PREP Act declaration”) that provides immunity from tort liability (except for willfull misconduct) for claims of loss caused, arising out of, relating to, or resulting from administration or use of countermeasures to diseases, threats and conditions determined by the Secretary to constitute a present, or credible risk of a future public health emergency to entities and individuals involved in the development, manufacture, testing, distribution, administration, and use of such countermeasures.

    The PREP Act also authorizes an emergency fund in the United States Treasury to provide compensation for injuries directly caused by administration or use of a countermeasure covered by the Secretary’s declaration. While no funds have been appropriated for this purpose, if funds are appropriated, compensation may then be available for medical benefits, lost wages and death benefits to individuals for specified injuries.
    cdc.gov/h1n1flu/eua/qa.htm

    What are Clinical Trials:
    Clinical trials, also known as clinical studies, are research studies in which scientists and doctors test new drugs and treatments to see if they will improve health. Many of today's treatments for cancer are based on the results of past clinical trials. Because of progress made through clinical trials, many people treated for cancer are now living longer.

    Clinical trials are divided into four phases.
    Phase 1 trials: These trials are the first time a new drug or treatment is given to humans. They are normally carried out in a small number of volunteers (typically 6-20 people) who may include healthy volunteers or patients with the disease for which the product is intended as a treatment in order to find out how safe the treatment is. They also look at how a new drug should be given (by mouth, injected into muscle or the bloodstream, etc.), how often and at what dose. Phase 1 trials can also involve patients for whom standard therapies have failed and for whom no other therapies are available.

    Phase 2 trials: These trials involve larger numbers of people (typically 12 - 50). Phase 2 trials continue to look at safety of the therapy but also test how well the new drug or treatment works in patients with different disease types.

    Phase 3 trials: These are large studies (100+ people) that look at how well a new drug or treatment works in comparison to current therapies to see which treatment is better. Those taking part are usually divided into two treatment groups: standard treatment versus new treatment.

    Phase 4 trials: These trials are usually carried out after the drug or treatment has been approved by the FDA and is readily available for use in the general patient population. The purpose of Phase 4 trials is to continue to study the effects of the drug or treatment on different populations and to look for side effects associated with long-term use.
    Back to Top

    What is a Protocol:
    Clinical trials use written guidelines called protocols. The protocol explains what the trial hopes to accomplish, how the trial will be carried out, and why each part of the trial is necessary. For example, the protocol includes:

        * The reason for doing the trial
        * How many people will be in the trial
        * Who is eligible to take part in the trial
        * What study drugs participants will need to take
        * What medical tests participants will have and how often
        * What information will be gathered

    Every doctor or research center that takes part in the trial uses the same protocol. This makes sure that patients are treated identically no matter where they are receiving treatment, and that information from all the centers taking part can be combined and compared.

    Why Slow Production for Traditionally Produced (chicken eggs) Swine Flu Vaccine:
    One dose of swine flu vaccine for every two eggs, compared with two doses of seasonal flu vaccine per egg
    http://www.boston.com/business/healthcare/articles/2009/10/22/quest_for_swine_flu_vaccine_giving_some_firms_a_boost/

    _____________________
    Brief Overview of Categories of H1N1/ Vaccine Investment Plays:

    I - Vaccines / Prevention
    1) Production Method / Capacity plays (NASDAQ:NVAX) (NASDAQ:VICL) (NYSE:NVS) (NYSEMKT:INO)
    2) Nationalistic / Population Size Play (SVA - China) (NVAX - India)
    3) Injection / Vaccine support services (syringes etc.) (NYSE:BAX) (NYSE:BDX)
    4) Outsourced production plays
    5) Bio -Defence (MDCGF - France)
    6) Anti-Mutation / Pan-Influenza Play (NYSEMKT:CVM) (NYSEMKT:NNVC) (INO)
    7) Universal Flu Vaccine Play (INO)

    II - Treatment After Infection Occurs:
    1) Dealing with severe lung infections (Fludase® (DAS181)) (NYSE:CBM) (OTCQB:AEMD)
    2) ICU treatments (NASDAQ:BCRX) (NYSE:GSK) (NYSE:ROG)
    III - Population Avoidance:
    1) masks/ disinfectants… Surgical masks are good enough (NYSEMKT:APT) (NYSE:MMM) (NYSE:CLX) (NYSE:ECL) (OTCQB:PURE)

    IV - Testing do you have it? (NASDAQ:GPRO)
    1) Test kits - (NYSE:DGX)

    V - Merger / Acquisitions / Licensing (VICL) (NVAX)
    _____________________
    Sorry this is still a graphic instead of a table. I played with the table tool, but its a
    PITA to work with.

    Swine Flu Companies Discussed and Their Web Sites


    _____________________
    Swine Flu Hits Stuffed Animal World:



    2009 H1N1 Flu Outbreak Map:
    The Link is from DoubleGuns
    flutracker.rhizalabs.com/

    I am not too happy with any of the outbreak maps. They all make the same mistake, they try to show the worlds data on one chart. This makes them SLOW.
    I will keep looking for one that works faster.
    _____________________

    Red Cross Tips For Dealing With The Flu:

    IF YOU ARE ILL -
    * Stay in a room separate from common areas of the home and avoid contact with others as much as possible.

    * Stay at home for at least 24 hours after their fever is gone without using medicine to reduce the fever.

    * Get lots of rest and drink plenty of fluids.

    * Consider wearing a facemask, if available and tolerable, when sharing common spaces with household members. (ed - surgical masks ok).

    * Check with your healthcare provider about whether to take antiviral medication, or if fever persists, whether antibiotics are needed.

    WHEN CARING FOR SOMEONE WHO HAS THE FLU -
    *Disinfect door knobs, switches, handles, toys and other surfaces that everyone touches.

    * Use detergent and very hot water to do dishes and wash clothes. It's okay to wash everyone's dishes and clothes together. Wash your hands after handling dirty laundry.

    * Designate only one adult as the caregiver. People at increased risk of severe illness from the flu should not be caregivers.

    * Although not mentioned by the Red Cross, the caregiver should probably ware a surgical mask as well when entering the sick room.

    * Deal with crisis situations calmly and confidently to give the best support to the person being cared for.
    _____________________

    MayoClinic.com Provides Credible, Up-to-Date Information And Decision-Support Tools For Flu Season

    Click here to link to the Mayo tool:
    www.mayoclinic.com/health/flu-symptoms/F...

    _____________________
    Suggeted Protocol For Schools To Decide When Flu Should Trigger A Shutdown
    www.medicalnewstoday.com/articles/169984.php

    After comparing more than two dozen possible scenarios for closing a school, the analysis suggested three optimal scenarios:

    1. A single-day influenza-related absentee rate of 5 percent

    2. Absenteeism of 4 percent or more on two consecutive days

    3. Absenteeism of 3 percent or more on three consecutive days


    Older references are stored in the MEMORY ALPHA REFERENCE LIBRARY
    http://seekingalpha.com/instablog/283977-user-283977/37565-memory-alpha-reference-library





    Disclosure: NVAX, NNVC, SVA, VICL (sometimes trading, sometimes holding)
Back To FocalPoint Analytics' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (53)
Track new comments
  • Freya
    , contributor
    Comments (2265) | Send Message
     
    Medicago is on the move. I don't know if its because its not well known and on the Pinks or whether its because of the Serious nature of the Avian Flu.

     

    We are watching the ones that rose previously but MDCGF is rising despite the drops in other like companies.

     

    What it has going for it besides the Flu is the Biodiesel side. I haven't seen anything about it for about a month but it just keeps chugging like the "Little Train that Could".
    11 Dec 2009, 11:04 PM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5803) | Send Message
     
    Author’s reply » Hi Freya
    Medicago (MDCGF) tells a great story. They are partnered with Philip Morris because they use tobacco plants to generate their new approach to vaccine production. They seem to have several other positives going for them as well.

     

    The problem with Medicago concerns buying and selling it. On my trading platform (Wells) the latest price information as of right now (12/12 at 11am eastern) is .7498. But when I go to Medicago's web site:

     

    www.medicago.com/Engli...

     

    they list the price at .79 at 2/11 3:59. So even on their own web site, they still don't have final pricing for 12/11 even though it's now 11am Eastern on 12/12. Beware of the commissions with it as well.

     

    I once owned 40k shares of Medicago, the price presumably went up big, but on selling, I found the price was not anywhere near the price listed on their web site. So based on my experience, I suggest caution until they move the stock to a more responsive exchange.
    12 Dec 2009, 11:23 AM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5803) | Send Message
     
    Author’s reply » (December 11) Chinese health officials step up flu prevention

     

    BEIJING – China's Health Ministry warned Friday that the swine flu outbreak in the country could peak over the next several months, especially as hundreds of millions of people return home for the traditional Chinese New Year.

     

    "Large numbers of travellers during the Lunar New Year period in late January and February may hamper our efforts to control the spread of the flu," ministry spokesman Deng Haihua said in a statement.

     

    More than 100,000 people in China have been infected with swine flu, and the number of swine flu deaths more than tripled in two weeks near the end of November with the onset of winter, according to the official Xinhua News Agency.

     

    China's peak flu season, which could last from now until March, will be a critical period for flu control and prevention, Deng said.

     

    An average of 1 million people are vaccinated every day, and the ministry aims to increase that to 1.5 million before the Lunar New Year, Deng said.
    news.yahoo.com/s/ap/20...

     

    (ed: It seems to me this will result in more H1N1 vaccine orders from SVA).
    12 Dec 2009, 12:13 PM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5803) | Send Message
     
    Author’s reply » (December 15) Positive H1N1 (Swine Flu) Virus Initial Pilot Animal Study May Support Use Of SinoFresh Nasal Spray As Preventative Measure

     

    SinoFresh Healthcare, Inc., (PINKSHEETS: SFSH) announced the recent successful initial animal pilot study of the SinoFresh Nasal Spray product for use in preventing and decreasing the severity of H1N1 ("swine flu") virus. Additional testing necessary for FDA approval of the product for this use, as well as a product specifically targeted at cold and flu including H1N1, is planned. The study suggests that SinoFresh Nasal Spray use allowed the H1N1 infected animals to recover more rapidly than did untreated animals.
    You can get this at www.buysinofresh.com/
    www.medicalnewstoday.c...

     

    (ed: I included this for completeness. It’s a 7 cent stock as of this posting.)
    15 Dec 2009, 09:38 AM Reply Like
  • doubleguns
    , contributor
    Comments (7886) | Send Message
     
    USER. I can't even get my animals to let me put meds in their ears. What a fiasco it must be putting that in the noses of animals. I would not want to be the person administering that med in the animal trials.

     

    I'm sure it would be humorous to watch.
    15 Dec 2009, 09:45 AM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5803) | Send Message
     
    Author’s reply » LOL... I can just see you trying that on your animals Guns.

     

    Our cat's nose is all stuffed up, and cat's will not eat if they can't smell their food.... So the vet recommended spraying something called "Little Noses" a saline solution. One way we have done it is to wrap him in a blanket so he can't use his weapons... even than he lets us know what he thinks about that. Last night, I tried a more stealthy approach.. I brought the bottle next to his nose. He inquisitively sniffed it , I squirted .... hehehehe I doubt he will fall for that trick twice. At any rate, it does seem to be helping.
    15 Dec 2009, 10:05 AM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5803) | Send Message
     
    Author’s reply » (December 15) 800,000 doses of kids' swine flu vaccine recalled

     

    By Mike Stobbe, AP Medical Writer:
    Health officials are recalling hundreds of thousands of doses of swine flu vaccine after tests indicated they may not be potent enough to protect against the virus.

     

    The Centers for Disease Control and Prevention notified doctors about the recall Tuesday. The recall involves about 800,000 doses made by Sanofi Pasteur. The doses are pre-filled syringes intended for young children, ages 6 months to almost three years.

     

    Health officials recommend children those ages get two doses, spaced about a month apart.

     

    Health officials say it's not clear how many doses have already been given, but they don't think children need to be re-vaccinated. The lots passed potency tests when they were first shipped, but tests indicate the potency waned after.
    finance.yahoo.com/news...

     

    (ed: The explanation does not pass the smell test. If this decrease in potency was the norm, it suggests that the shelf life is quite limited. This means you can't stock-pile it. Are the children that received this protected? It sounds to me like the company tried to increase revenues by watering down the vaccine to the point of its loosing its potency much sooner than its normal shelf life.)
    15 Dec 2009, 11:58 AM Reply Like
  • robert.b.ferguson
    , contributor
    Comments (10803) | Send Message
     
    User: Greetings. Good luck with your feline friends. Are any of those doses already in China?
    15 Dec 2009, 12:08 PM Reply Like
  • Mayascribe
    , contributor
    Comments (9597) | Send Message
     
    User: You look as if someone stole your Cheeze-its!

     

    SanofiAventis (SNY) recalls 800,000 pediatric dosages:

     

    www.marketwatch.com/st...

     

    Thanks to YH for the tip on this one. No biggy, only that the dosages were possibly a little too weak. No harm, no adverse effects involved. Currently, SNY is down 0.59%.
    15 Dec 2009, 01:50 PM Reply Like
  • Mayascribe
    , contributor
    Comments (9597) | Send Message
     
    SVA up 3.93%. If I could figure out SVA's charts...
    15 Dec 2009, 01:57 PM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5803) | Send Message
     
    Author’s reply » Robert... those recalls are in the US market.
    15 Dec 2009, 02:55 PM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5803) | Send Message
     
    Author’s reply » Maya - There has hardly been any vol on SVA lately. Its all low vol moves... Average vol is 3M shares. Today is the first day in a long time with 1M vol. Interestingly, the stock is moving up.
    15 Dec 2009, 03:05 PM Reply Like
  • optionsgirl
    , contributor
    Comments (5045) | Send Message
     
    *
    QUICK CHAT #28: Start 12/15/09 after Market Close [Edit or Delete]2 comments
    Dec 15, 2009 05:09 PM
    o
    Font Size:
    o
    Print
    o Email
    o TweetThis
    Jim Chanos: Short China

     

    businessinsider.com/ji...-...
    Themes: Jim Chanos

     

    Back To optionsgirl's Instablog HomePage »

     

    Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.
    This post has 2 comments:

     

    Register or Login to rate comments »
    *

     

    o SAS70:
    o Comments (122)
    o Follow
    OG picked up 3500 NVAX @ 2.78 today. It closed at 2.90 and is down to 2.89 in after hours at the moment anyways. Do you know what's happening there yet?

     

    Thanks
    Dec 15 06:14 PM |Report abuse | Link | Reply
    0 0
    *

     

    o optionsgirl:
    o Comments (1946)
    o • Instablog (117)
    o • StockTalk (43)
    o Follow
    Re: India News:
    Message Boards > Business & Finance > Investments > Stocks (A to Z) > Stocks N > Novavax, Inc.
    View all Topics | View all Messages < Newer Topic | Older Topic >
    India News - ICMR will on Tues review the trial performance 15-Dec-09 11:54 am
    from the news article below: "Meanwhile, a team of experts from ICMR will on Tuesday review the trial performance of the H1N1 vaccine developed by Cadilla Pharma through virus-like particle (VLP) technique."

     

    TOP NEWS
    Swine flu shots by Jan
    DNA Correspondent
    312 words
    15 December 2009
    DNA - Daily News & Analysis

     

    Centre to import vaccine; Serum Institute to develop drops by Apr

     

    Imported vaccine for the H1N1 influenza will be available in Rajasthan by January 2010. The vaccine will help fight the second wave of H1N1, which many doctors say could be more severe.

     

    "The companies to supply the vaccine to India have already been shortlisted. Government is also moving fast to sort out the issues related to placing order to these international pharmaceutical companies for the H1N1 vaccine," VM Katoch, director of Indian Council of Medical Research (ICMR), told DNA over phone.

     

    The Rajasthan government is already in process of preparing the list of health workers and other authorities who are exposed to H1N1 threat while discharging their duties. "The list prepared so far includes health workers who are directly exposed to the H1N1 virus. But if need arises, we will also prepare a list of important people in government and administration for vaccination," state health minister AA Khan said.

     

    Indian pharmaceutical companies have made strides in process of development of indigenous H1N1 vaccine as one company has already entered the human trial phase while three more have completed tests on animals.

     

    Meanwhile, a team of experts from ICMR will on Tuesday review the trial performance of the H1N1 vaccine developed by Cadilla Pharma through virus-like particle (VLP) technique. "Virus-like particle (VLP) vaccines typically comprises multiple copies of a protein antigen that when assembled together mimic the conformation of native virus. The protein shell that coats a virus, called capsid is an important component of a vaccine," Katoch said.

     

    He also informed that another company, Zydus Cedilla has also begun human trial for their H1N1 vaccine while three other Indian companies - Serum Institute of India, Panacea and Bharat Biotech are preparing to submit their test results of animal trials in India.
    15 Dec 2009, 06:54 PM Reply Like
  • Freya
    , contributor
    Comments (2265) | Send Message
     
    OG: lnre HOGS

     

    www.bloomberg.com/apps...

     

    Human flu to Pig, Shanghai
    15 Dec 2009, 11:40 PM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5803) | Send Message
     
    Author’s reply » For Swine Flu News Concentrator readers... Re OG's above post:
    Cadilla Pharma is the India company that has a partnership with (NVAX). They are in the process of building a manufacturing facility in India to generate and sell NVAX's VLP technology based vaccines. While most people recognize (SVA) as a large population investment play, NVAX is also a large population investment play because of its partnership with Cadilla Pharma in India.
    16 Dec 2009, 01:00 PM Reply Like
  • optionsgirl
    , contributor
    Comments (5045) | Send Message
     
    We saw that in Minnesota, too, where the human virus was carried by the pigs.
    We see that the hogs can still be eaten so long as they are cooked properly. I can see the Chinese authorities telling the people to cook it well done, not try to kill their livestock or take away their protein.
    Anyone have any thoughts and what this leads to- first thing that comes to mind is maybe this is a mutation that can land back in the people population.
    What else might happen?

     

    On Dec 15 11:40 PM Freya wrote:

     

    > OG: lnre HOGS
    >
    >
    > www.bloomberg.com/apps...;sid=awamVRIai_uo
    >
    >
    > Human flu to Pig, Shanghai
    16 Dec 2009, 01:14 PM Reply Like
  • optionsgirl
    , contributor
    Comments (5045) | Send Message
     
    plus they are going to use this technology for other innoculations besides swine flu.

     

    On Dec 16 01:00 PM User 283977 wrote:

     

    > For Swine Flu News Concentrator readers... Re OG's above post:<br/>Cadilla
    > Pharma is the India company that has a partnership with (NVAX). They
    > are in the process of building a manufacturing facility in India
    > to generate and sell NVAX's VLP technology based vaccines. While
    > most people recognize (SVA) as a large population investment play,
    > NVAX is also a large population investment play because of its partnership
    > with Cadilla Pharma in India.
    16 Dec 2009, 01:15 PM Reply Like
  • Mayascribe
    , contributor
    Comments (9597) | Send Message
     
    NVAX is back on the investment map (for me), especially since on the 9th, they closed out their 6.8 million share offering at $3.30/share, raising about $21M.
    16 Dec 2009, 01:22 PM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5803) | Send Message
     
    Author’s reply » (December 16) Novartis Increases China Commitment: Opens Suzhou Plant, Technical R&D Center - ChinaBio Today

     

    Novartis is heavily committed to increasing its presence in China. Last month, the company announced it would spend $1 billion over the next five years on an R&D center in Shanghai (see story). Besides the desire to take advantage of China’s R&D opportunities, Novartis aims to make China one of its top three markets in the world.

     

    See ChinaBio Today's article on SA for the full info:
    seekingalpha.com/artic...
    16 Dec 2009, 03:21 PM Reply Like
  • Mayascribe
    , contributor
    Comments (9597) | Send Message
     
    Looks like the market is taking those 800,000 recalled SanofiAventis dosages okay. SNY up 52 cents today.
    16 Dec 2009, 03:37 PM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5803) | Send Message
     
    Author’s reply » (December 17 - Reuters) Germany and Spain seek to cut H1N1 vaccine orders
    Germany and Spain want to reduce deliveries of swine flu vaccine and potentially return excess supplies to manufacturers, due to low uptake of the shots, in a move that could hit drugmakers' profits.

     

    Germany's health ministry said on Thursday that some German states had been in talks with Britain's GlaxoSmithKline (GSK) about reducing deliveries of H1N1 vaccine, but the talks had as yet yielded no results.

     

    Spain's health minister Trinidad Jimenez said her country was negotiating with the producers of H1N1 vaccine to return excess stock, after people considered at high-risk from the new flu virus largely snubbed a vaccination campaign.

     

    "The contracts signed with the companies from which we acquired the vaccines included clauses which allow the return of unused vaccines to the companies so they can be distributed to other countries," Jimenez added.

     

    Germany ordered 50 million doses of H1N1 vaccine from Glaxo, while Spain bought 22 million doses from Novartis (NOVN), 14.7 million from Glaxo and 400,000 from Sanofi-Aventis (SASY).

     

    Analysts at Morgan Stanley said revenues generated from swine flu were expected to total $600 million for Novartis, 2.2 billion pounds ($3.6 billion) for Glaxo and 750 million euros ($1.1 billion) for Sanofi, to be booked in the last quarter of 2009 and first three months of 2010. "The return of excess quantities by Germany and Spain creates downside risk of up to 15 percent of total swine flu revenues for these companies," they said.
    www.reuters.com/articl...
    17 Dec 2009, 02:40 PM Reply Like
  • robert.b.ferguson
    , contributor
    Comments (10803) | Send Message
     
    Wait for it: Dip buying!

     

    On Dec 17 02:40 PM User 283977 wrote:

     

    > (December 17 - Reuters) Germany and Spain seek to cut H1N1 vaccine
    > orders
    > Germany and Spain want to reduce deliveries of swine flu vaccine
    > and potentially return excess supplies to manufacturers, due to low
    > uptake of the shots, in a move that could hit drugmakers' profits.
    >
    >
    > Germany's health ministry said on Thursday that some German states
    > had been in talks with Britain's GlaxoSmithKline (GSK) about reducing
    > deliveries of H1N1 vaccine, but the talks had as yet yielded no results.
    >
    >
    > Spain's health minister Trinidad Jimenez said her country was negotiating
    > with the producers of H1N1 vaccine to return excess stock, after
    > people considered at high-risk from the new flu virus largely snubbed
    > a vaccination campaign.
    >
    > "The contracts signed with the companies from which we acquired the
    > vaccines included clauses which allow the return of unused vaccines
    > to the companies so they can be distributed to other countries,"
    > Jimenez added.
    >
    > Germany ordered 50 million doses of H1N1 vaccine from Glaxo, while
    > Spain bought 22 million doses from Novartis (NOVN), 14.7 million
    > from Glaxo and 400,000 from Sanofi-Aventis (SASY).
    >
    > Analysts at Morgan Stanley said revenues generated from swine flu
    > were expected to total $600 million for Novartis, 2.2 billion pounds
    > ($3.6 billion) for Glaxo and 750 million euros ($1.1 billion) for
    > Sanofi, to be booked in the last quarter of 2009 and first three
    > months of 2010. "The return of excess quantities by Germany and Spain
    > creates downside risk of up to 15 percent of total swine flu revenues
    > for these companies," they said.
    > www.reuters.com/articl...
    17 Dec 2009, 03:36 PM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5803) | Send Message
     
    Author’s reply » (December 21) H1N1 Cases Still Increasing In Many Countries; WHO To Begin Shipping Donated Vaccines Within Weeks

     

    With many countries continuing to report a growing number of H1N1 (swine flu) cases, Keiji Fukuda, special adviser to the WHO director general on pandemic influenza, said Thursday it was too early to declare the pandemic over, the Washington Post reports. "Fukuda said that while the second wave of infections has peaked in the United States and some other countries in the Northern Hemisphere, the level of flu activity remains high elsewhere - in some European countries, including Switzerland and the Czech Republic, and in parts of Central Asia, such as Kazakhstan," according to the newspaper.

     

    "The pandemic is a global event. It is not simply a regional event," Fukuda said during a briefing (Stein, 12/18). "Fukuda also noted that the signs of a peak and a decline in the caseload in North America and parts of Europe had occurred 'extraordinarily early for influenza,' with several months of the winter left," Agence France-Presse reports. "As a result, the WHO could not rule out the possibility of another wave of illness in late winter or early spring".
    www.medicalnewstoday.c...
    21 Dec 2009, 10:23 AM Reply Like
  • Freya
    , contributor
    Comments (2265) | Send Message
     
    And here I was bringing the above link to your attention.

     

    2nd wave? A lot of talk about it but I believe the question should be what was the first Wave? I mean, which type and where. Does catching one version make you susceptible to another version? Can one drug protect against all variants that we know about currently?

     

    Our Flu season end when, in Feb.? Well this flu ignored our normal flu season and continued to spread from April, that we know of. It hit Mexico first, jumped borders and infected the world without regard to Normal Flu Seasons anywhere. The thing is, that there are at least 3 distinct variants and just because you beat off one, doesn't mean you aren't more vulnerable to another.

     

    After all, those receiving the current vaccines are gearing the Body's Immune system in a specific direction.

     

    Just a thought or 40.
    22 Dec 2009, 04:59 AM Reply Like
  • Freya
    , contributor
    Comments (2265) | Send Message
     
    robert, not to worry, wait a few days, whatever is done can be undone.

     

    My Email address is available to who knows how many. If you are corresponding with anyone in the group, ask and Ye Shall Receive. After my experience with Jason, I no longer trust any site.

     

    That goes for you too Cheeseless Mouse. You should still have my old Email, send me another msg., I'll send you my encrypted site.
    22 Dec 2009, 05:11 AM Reply Like
  • H. T. Love
    , contributor
    Comments (17297) | Send Message
     
    (VICL): announced today the issuance of U.S. Patent No. 7,628,993 covering DNA vaccines for herpes simplex virus type 2 (HSV-2). HSV-2 is a sexually transmitted virus which is the leading cause of genital herpes. Vical is collaborating under a previously disclosed grant(1) on the preclinical development of an HSV-2 vaccine which will be designed for use in people already infected with HSV-2, with the goal of reducing or eliminating periodic viral flare-ups and the associated viral
    shedding and transmission. The vaccine will be evaluated with Vical's
    Vaxfectin(R) adjuvant.

     

    The new '993 patent covers DNA vaccines targeting a specific HSV-2 protein, formulated with or without Vical's Vaxfectin(R) adjuvant. It adds to Vical's family of patents in the United States and other key regions based on the company's discovery that administering genetic sequences such as DNA or RNA into the body, without the use of viral delivery vehicles, may cause expression of the proteins encoded by the genetic sequences. Vical has additional issued patents covering the composition and use of the Vaxfectin(R) adjuvant.

     

    DNA vaccines encode certain proteins associated with a target pathogen, rather than using any part of the pathogen itself, and can prime the immune system as well as induce potent antibody and T-cell immune responses. DNA vaccines contain no viral particles, are non-infectious, and can be administered on a repeat basis without unwanted immune responses. Additionally, DNA vaccines have the potential to achieve proof of concept more quickly and cost-effectively than conventional vaccines, and can be manufactured using uniform methods of fermentation and purification, allowing significantly faster development and production.

     

    HSV-2 Disease Burden

     

    HSV-2 infections are persistent and result in periodic virus shedding. In the United States, at least 40 million people are infected with HSV-2, and approximately 1.6 million people are newly infected each year, with approximately 500,000 of those suffering from disease symptoms. Even higher infection rates are evident in developing countries, with further complications in people also infected with HIV. There is currently no approved vaccine for HSV-2. Although antiviral regimens have become a standard of care, their inconvenience, cumulative cost over the years and potential for drug resistance highlight the need for safe, new approaches to reducing HSV-2 lesions, shedding, and transmission. Estimated direct costs of treating HSV-2 in the United States alone are close to $1 billion annually, primarily for drugs and outpatient medical care, plus additional indirect costs of more than $200 million.

     

    HardToLove
    22 Dec 2009, 07:37 AM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5803) | Send Message
     
    Author’s reply » (ed: note the last paragraph re SVA's Q4 earnings… )
    (December 22) Sinovac Named Among China's Top 10 Most Competitive Companies - ChinaBio Today

     

    Sinovac (SVA) was selected by China Business Media as one of China's Top 10 most competitive companies listed overseas for 2009.

     

    In Q3, SVA's revenues increased by 142%, jumping from $8.7 million to $21.4 million. Almost all of the growth came from flu vaccines, while the company’s hepatitis A vaccine’s sales were flat. Only the September month of Q3 saw significant flu revenues, implying Q4 could be a very strong quarter.
    seekingalpha.com/artic...
    22 Dec 2009, 09:27 AM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5803) | Send Message
     
    Author’s reply » That is huge news on (VICL) HT.
    22 Dec 2009, 09:27 AM Reply Like
  • tripleblack
    , contributor
    Comments (13440) | Send Message
     
    I agree. I am now looking at (VICL). What other products do they have a revenue stream from?

     

    On Dec 22 09:27 AM User 283977 wrote:

     

    > That is huge news on (VICL) HT.
    22 Dec 2009, 09:30 AM Reply Like
  • tripleblack
    , contributor
    Comments (13440) | Send Message
     
    Background data, found a new source for news in Bulgaria:

     

    22 December 2009 | 13:50 | FOCUS News Agency

     

    Bucharest. Romania registers 37 fatalities in patients infected with the A/H1N1 flu virus, as three more patient died in the past 24 hours, the Health Ministry said Tuesday, Mediafax reports.
    The number of infections increased with 50 new cases in the past 24 hours, taking the total number to 5,297.
    According to the Health Ministry, new AH1N1 infection cases were registered in capital city Bucharest (14), Cluj (13), Brasov (5), Sibiu (4), Arges and Maramures (2 cases each), Alba, Bacau, Bihor, Covasna, Galati, Harghita, Prahova, Valcea and Vrancea (1 case each).
    22 Dec 2009, 09:52 AM Reply Like
  • robert.b.ferguson
    , contributor
    Comments (10803) | Send Message
     
    Hi Gang: I'm off to the dirt for a short while I will post snaps when I get back.
    22 Dec 2009, 09:56 AM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5803) | Send Message
     
    Author’s reply » triple - VICL is an exciting start-up…

     

    it concentrates on DNA delivery technologies for the prevention and treatment of serious diseases. For example, one of their programs, Allovectin-7 is immunotherapy for mestatic melanoma.

     

    Another of the products they are working on is VAXFECTIN. This is an adjuvant used to ENHANCE (Boost) other vaccines effectiveness. Used in dose-sparing mode it would be critically important in extending limited vaccine supplies to protect the greatest number of people.

     

    For example Sanofi Pasteur's Fluzone formulated with Vaxfectin allowed a nearly 10 fold reduction in vaccine dose while generating equivalent or better antibody responses compared with the same vaccine not formulated with Vaxfectin. The same stuff works with different vaccines.. for example it extends H5N1 vaccine.

     

    Used in BOOST mode, they are working with another research team to develop a Vaxfectin formulated preventive DNA vaccine against HIV. A Vaxfectin formulated cancer vaccine resulted in approximately a 100 fold increase in antigen specific CD8+ T cell responses compared with unformulated vaccines…

     

    They are working on TransVax - a vaccine that prevents viral reactivation and disease after transplant. They are also working on CyMVectin a vaccine designed to prevent infection before and during pregnancy to preclude fetal transmission.

     

    They have partnerships with AnGes, Sanofi-aventis, Merck, and Aqua Health Ltd. (Novartis (NVS)).

     

    Its definitely a start-up technology type company, but DNA vaccine technology is the future. It’s one of my long term investments in bio-tech. It will likely just sit there for some time, but it has serious "pop" potential. Here is the URL for their web site:
    www.vical.com/
    22 Dec 2009, 10:38 AM Reply Like
  • H. T. Love
    , contributor
    Comments (17297) | Send Message
     
    On Dec 22 10:38 AM User 283977 wrote:

     

    > triple - VICL is an exciting start-up…
    > <snip>
    > Another of the products they are working on is VAXFECTIN. This is
    > an adjuvant used to ENHANCE (Boost) other vaccines effectiveness.
    > Used in dose-sparing mode it would be critically important in extending
    > limited vaccine supplies to protect the greatest number of people.

     

    And don't forget their "potential cross strain protection" work which allows vaccination against flus that don't have an exact DNA match. If that proves effective and has broad applicability, it's a geme-changer.

     

    This is formulated to be used with their VAXFECTIN product.

     

    HardToLove
    22 Dec 2009, 11:01 AM Reply Like
  • optionsgirl
    , contributor
    Comments (5045) | Send Message
     
    Even though the return of vaccine products will impact the manufacturers (to the extent they can't sell them somewhere else) look whose trying to return the product-countries in serious doo doo- Spain. It's another tell to watch Eurozone.
    22 Dec 2009, 11:43 AM Reply Like
  • Freya
    , contributor
    Comments (2265) | Send Message
     
    NVAX is working on a Triple Cocktail, a combination vaccine. With its fast development, it could be available by next flu season. Combine this with the ability to set up Labs quickly. They may be the go to guys in a few months.
    22 Dec 2009, 01:27 PM Reply Like
  • Freya
    , contributor
    Comments (2265) | Send Message
     
    Most of these small companies have a tremendous amount of Shorts, moves to the Upside may trigger violent but short lived upswings.
    22 Dec 2009, 01:30 PM Reply Like
  • tripleblack
    , contributor
    Comments (13440) | Send Message
     
    Major News I just noticed:

     

    Matthew Perrone and Marilynn Marchione, Associated Press Writers, On Tuesday December 22, 2009, 7:14 pm EST
    WASHINGTON (AP) -- Drugmaker MedImmune is recalling nearly 5 million doses of swine flu vaccine because the nasal spray appears to lose strength over time, federal health officials announced Tuesday.

     

    The vaccine recall is the second this month caused by declining potency and comes as public health officials urge millions of Americans to get vaccinated against swine flu.

     

    The action affects more than 4.6 million doses, but the vast majority have already been used, according to the Food and Drug Administration. Agency officials said the vaccine was strong enough when it was distributed in October and November.

     

    "The slight decrease in potency is not expected to have any effect on the protective effect of the vaccine," said Norman Baylor, director of the FDA's vaccine research office. "We are not recommending revaccination."

     

    The agency is looking into the problem but said it's not uncommon for vaccines to lose strength over time. MedImmune's vaccine has a recommended shelf life of about four months. The company has about 3,000 doses in its warehouses but does not know how many remain in the field, according to the FDA.

     

    Last week, vaccine maker Sanofi Pasteur recalled hundreds of thousands of swine flu shots for children because tests indicated those doses lost some strength. Most of those doses had already been used, too.

     

    Maryland-based MedImmune, a subsidiary of London-based AstraZeneca PLC, voluntarily recalled 13 lots of its vaccine, "due to a slight decrease in potency" discovered through routine quality control testing, said spokesman Tor Constantino.

     

    "It's not a safety concern. People who have received doses from the affected lots do not need to be revaccinated. The doses were well within potency specification," he said.

     

    Swine flu vaccine has been available since early October, and since then manufacturers have released over 111 million doses for distribution in the U.S. MedImmune makes the only nasal spray version, which can be used by healthy people ages 2 to 49.

     

    Only in recent weeks have state authorities lifted restrictions on who can get vaccinated. Previously the vaccines were reserved for high-risk patients, including pregnant women and schoolchildren.

     

    In a telephone news conference on Tuesday, Dr. Anne Schuchat of the federal Centers for Disease Control and Prevention estimated that 60 million Americans have received swine flu vaccine, and said intense monitoring for side effects has not turned up any safety concerns.

     

    "We are not seeing any worrisome signs," she said.

     

    The vaccine supply has increased so much in recent weeks that she urged parents of children 10 and younger to get them a second dose, because studies show this age group needs two for optimal protection.

     

    Flu activity has slowed, but "it's not gone," Schuchat said. "None of us know what the weeks and months ahead will bring in terms of influenza activity, and it's very important not to become complacent."

     

    The first wave of the swine flu pandemic began in April, when the strain was discovered. A larger wave started in the late summer and is declining. Infections are now widespread in 11 states, down from 48 in late October.

     

    A new Harvard poll released Tuesday finds that concern about swine flu has waned along with the number of new cases being reported.

     

    Only 40 percent of people now say they are concerned that they or a family member will get sick from swine flu during the next year. That's down from an earlier poll in September, when 52 percent said they were worried about swine flu.

     

    The new poll found that most parents who sought vaccine for their children were able to get it. However, more than one-third of respondents said they did not plan to seek it for their kids.

     

    The Harvard School of Public Health polled more than 1,600 adults on Dec. 16 and 17.

     

    Also on Tuesday, a 13-year-old dog in suburban New York was confirmed as the first known case of swine flu in a dog. The pet apparently caught the virus from his owner. The CDC's Schuchat said that animals can carry and spread flu viruses, but such cases are rare and people should not be afraid to enjoy their pets. A few cats and ferrets have also been diagnosed with swine flu.

     

    AP Medical Writer Marilynn Marchione reported from Milwaukee.
    22 Dec 2009, 08:43 PM Reply Like
  • tripleblack
    , contributor
    Comments (13440) | Send Message
     
    www.dailymail.co.uk/ne...

     

    Dramatic News about stem cell developments.
    23 Dec 2009, 08:53 AM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5803) | Send Message
     
    Author’s reply » Backed up as of December 25 10:16 Pacific

     

    Merry Christmas!
    25 Dec 2009, 01:16 PM Reply Like
  • tripleblack
    , contributor
    Comments (13440) | Send Message
     
    OK, (CVM) has crossed a tripwire, now trading below $1.

     

    I am tracking it this Monday, with the idea that a buying opp. is likely. I have it set for a Buy@ of $.89, but I may pull the trigger at any time now.

     

    I am also watching (BCRX), (VICL) [thanks User, I like this one too], and of course (NVAX). All 3 are within 10% of a Buy on my list.
    27 Dec 2009, 08:27 AM Reply Like
  • H. T. Love
    , contributor
    Comments (17297) | Send Message
     
    VICL: announced that an independent Safety Monitoring Board (SMB) for the company's Phase 3 AIMM trial of Allovectin-7(R) in patients with metastatic melanoma has completed the trial's third scheduled safety analysis and recommended that the trial continue per the protocol. The trial is expected to complete enrollment of the planned 375 subjects in the next few weeks.

     

    About the AIMM Trial

     

    Vical is conducting the AIMM (Allovectin-7(R) Immunotherapeutic for
    Metastatic Melanoma) trial, a Phase 3 pivotal trial of the company's
    Allovectin-7(R) cancer immunotherapeutic as first-line therapy in approximately 375 chemotherapy-naive patients with Stage III or IV metastatic melanoma in accordance with a Special Protocol Assessment (SPA) agreement completed with the U.S. Food and Drug Administration (FDA). The SPA specifies the trial objectives and design, clinical endpoints, and planned analyses expected to be needed for product approval. The AIMM trial is currently enrolling patients at clinical sites in key centers worldwide.

     

    Under a previously announced collaborative agreement, AnGes MG, Inc., is funding the AIMM trial through a series of cash payments and equity investments. Vical has received the full $22.6 million committed by AnGes. In exchange for funding the trial, AnGes received exclusive marketing rights in Japan and other key Asian countries, and Vical is obligated to pay AnGes tiered royalties based on defined sales levels in the United States, and fixed royalties on rest-of-world sales. AnGes is obligated to pay Vical royalties on product sales in the specified Asian countries, plus certain sales-based milestone payments if defined sales levels are achieved. Each company will be responsible for obtaining regulatory approvals in any countries where it plans to market Allovectin-7(R).

     

    About Allovectin-7(R)

     

    Allovectin-7(R) is a plasmid/lipid complex containing the DNA sequences encoding HLA-B7 and beta-2 microglobulin, which together form a Class I Major Histocompatibility Complex, or MHC-I antigen. Injection of Allovectin-7(R) directly into tumors is designed to stimulate an immune response against both local and distant metastatic tumors. Vical conducted a large Phase 2 trial evaluating Allovectin-7(R) immunotherapeutic as a single agent for patients with Stage III or IV metastatic melanoma. Based on advice from clinical experts and detailed guidance received from the FDA in an End-of-Phase 2 meeting, Vical designed the Phase 3 AIMM trial.

     

    Allovectin-7(R) has been granted orphan drug designation for the treatment of invasive and metastatic melanoma by the FDA's Office of Orphan Products Development. Orphan drug designation provides U.S. marketing exclusivity for seven years if marketing approval is received from the FDA, in addition to certain tax benefits for qualifying expenses.

     

    About Metastatic Melanoma

     

    The American Cancer Society estimated that more than 68,700 new diagnoses of, and approximately 8,650 deaths from, melanoma would occur in 2009 in the United States. Currently, there are no consistently effective therapies for advanced cases of metastatic melanoma where the cancer has spread to other parts of the body. The toxicity associated with FDA-approved treatments such as dacarbazine or interleukin-2 is often significant, resulting in serious or life-threatening side effects in many of the patients treated. Patients with metastatic melanoma often are treated off-label with drugs such as temozolomide, which has been approved by the FDA for the treatment of certain types of brain cancer but not for the treatment of metastatic melanoma. Temozolomide is an orally-delivered pro-drug that converts in the body into the same active compound as dacarbazine.

     

    HardToLove
    28 Dec 2009, 09:13 AM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5803) | Send Message
     
    Author’s reply » Thanks HT - here is a link to that announcment.
    ir.vical.com/releases.cfm
    28 Dec 2009, 09:39 AM Reply Like
  • H. T. Love
    , contributor
    Comments (17297) | Send Message
     
    (VICL) is running +21.87%, $3.35 @ 09:45

     

    HardToLove
    28 Dec 2009, 09:45 AM Reply Like
  • H. T. Love
    , contributor
    Comments (17297) | Send Message
     
    (NVAX): Short Interest increased +7.83% on the 12/15/09 report over the 11/30 report. Went to 13515238 from 12534129.

     

    Fails to deliver wasn't available yet (12/27/09) and I'm trying to come up with a useful new chart combining price. Problems are the scaling of the price and short/fails are so different they are difficult to combine in a large and still readable form. I'll get there though.

     

    HardToLove
    28 Dec 2009, 09:51 AM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5803) | Send Message
     
    Author’s reply » (December 28) Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that it has filed an application with China's State Food and Drug Administration to commence a human clinical trial for its vaccine against human enterovirus 71 (EV 71), which causes hand foot, and mouth disease (HFMD). This is the first clinical trial application for HFMD vaccine submitted in China.

     

    No vaccine or antiviral treatment is currently available for HFMD worldwide, though it has become a very serious problem in Asia in recent years. The disease is highly contagious and a growing number of HFMD cases have been reported in parts of Asia, including Mainland China, Hong Kong, Singapore, Korea, and Taiwan. According to China's Center for Disease Control (CDC) between January 1 and November 30 of this year, the disease has caused more than 400 deaths in China, where health authorities reported over 1.1 million HFMD infections, compared to about 200 reported H1N1 deaths. HFMD is common among infants and children, as most of the recently reported cases have occurred in children. Due to the severity of the disease epidemic, China authorities recognize the unmet medical need and are expected to support the launch of a HFMD vaccine as soon as possible. Therefore, Sinovac believes that fast track status for the reviewing process and approval may be granted.

     

    Sinovac is independently developing the EV 71 vaccine and will retain full commercialization rights of the vaccine upon approval. Created by Sydney University, the animal model showed cross protection and demonstrated that the vaccine is effective in animals. In addition, Sinovac is preparing to file a patent application covering the EV 71 vaccine.

     

    Weidong Yin, Chairman, President & CEO, stated, "We are very pleased to submit the clinical trial application for the EV 71 vaccine to the SFDA. Our ability to submit the application ahead of the projected 2010 timeline is a validation of the R&D capabilities of the team developing this vaccine. A vaccine against EV 71 represents a significant unmet medical need, given that there are not effective preventive therapeutic alternatives for this life threatening viral illness affecting infants and children. Based on current expectations, we anticipate that the EV 71 vaccine, subject to positive human clinical trial results and commercialization, represents a significant flagship product opportunity for the Company as well as an opportunity to improve the lives of children around the world."
    www.sinovac.com/Invest...

     

    (ed: SVA will be filling its 4th quarter report soon. It will likely report a very strong quarter.)
    28 Dec 2009, 09:53 AM Reply Like
  • tripleblack
    , contributor
    Comments (13440) | Send Message
     
    I had an order in for (VICL) early this morning, picked some up before the major part of the up. Got in at $3.31. I should have listened to you, User...

     

    (CVM) is trading at $.92 now, I am watching it closely.
    28 Dec 2009, 12:25 PM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5803) | Send Message
     
    Author’s reply » That's still a good price triple. VICL's DNA technology is more advanced than the VLP technology of NVAX. I would not be surprised if its acquired. I look at VICL as a long term hold investment as opposed to a trading stock.
    28 Dec 2009, 02:08 PM Reply Like
  • tripleblack
    , contributor
    Comments (13440) | Send Message
     
    Bought 2000 shares of (CVM) at $.89, per plan. Now trading at $.97.

     

    (NVAX) is now trading at $2.57, and trending lower.

     

    finance.yahoo.com/news...

     

    They seem to think the flu season is over...

     

    I think they are wrong, LOL, but I am not pulling the trigger on NVAX for a while yet.
    29 Dec 2009, 10:58 PM Reply Like
  • tripleblack
    , contributor
    Comments (13440) | Send Message
     
    An interesting take on charting (CVM):

     

    finance.yahoo.com/news...
    30 Dec 2009, 09:40 AM Reply Like
  • H. T. Love
    , contributor
    Comments (17297) | Send Message
     
    (VICL): Vical Confirms Advantages of DNA Technology Platform With Vaccine for H1N1 Influenza

     

    PDF: ir.vical.com/common/do...

     

    Selected excerpts:

     

    "publication of data
    documenting the successful pilot lot production and initiation of animal immunogenicity testing of a Vaxfectin(R)-adjuvanted DNA vaccine for H1N1 influenza before conventional vaccine manufacturers even received the seed virus needed to start production"

     

    "The U.S. Navy has awarded a contract for $1.25 million to support large-scale cGMP vaccine manufacturing and related clinical and regulatory preparations for a Phase 1 clinical trial of the company's vaccine against H1N1 pandemic influenza. The trial will be conducted in collaboration with the U.S. Naval Medical Research Center (NMRC), a biomedical research organization within the Navy, and is expected to begin within the next few weeks"

     

    "The company's vaccine against A/H1N1 pandemic influenza (swine flu) produced robust immune responses against the matching strain that were well above the accepted protection threshold in 100% of vaccinated mice and rabbits after a standard two-dose vaccine regimen. At least 75% of vaccinated animals achieved or exceeded the protection threshold after a single dose of vaccine. In further studies, the vaccine demonstrated robust immune responses in 100% of vaccinated animals against
    non-matching virus strains isolated from recent outbreaks in three distinct geographic locations - California, Texas and Mexico. Vical's vaccine would also be expected to provide similar robust immune responses against other swine-origin A/H1N1 influenza virus subtypes, supporting selection of a single A/H1N1 virus strain as the basis for the vaccine".

     

    More details in the PDF.

     

    HardToLove
    31 Dec 2009, 09:55 AM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5803) | Send Message
     
    Author’s reply » Please switch to the Current Swine Flu News Concentrator...
    2 Jan 2010, 07:26 PM Reply Like
  • FocalPoint Analytics
    , contributor
    Comments (5803) | Send Message
     
    Author’s reply » Backed up as of January 2, 2010, 4:34 PM Pacific
    2 Jan 2010, 07:34 PM Reply Like
  • Talavera
    , contributor
    Comments (13) | Send Message
     
    Tripleblack thank you I will grab some of cvm soon.
    2 Jan 2010, 11:07 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.